Treatment Preference for Weekly DPP-4 Inhibitors Versus Daily DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Alogliptin (Primary) ; Trelagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 30 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.
- 02 Aug 2017 New trial record